The results of the recent pharmacotherapy of apnea by cannabimimetic enhancement
(PACE) trial that studied the effects of dronabinol (a cannabinoid) on the effects of …

We stand by our position statement1 and respectfully disagree with Schears et al. 2 and
Takakuwa, 3 who advocate that there is sufficient evidence to support the use of both …

We were puzzled by the 2018 American Academy of Sleep Medicine (AASM) position
statement recommending obstructive sleep apnea (OSA) be struck from the list of medical …

In the United States, currently 29 states and the District of Columbia have enacted laws that
allow for the medical use of cannabis. The list of conditions that qualify a patient for the use …

The diagnosis and effective treatment of obstructive sleep apnea (OSA) in adults is an
urgent health priority. Positive airway pressure (PAP) therapy remains the most effective …

Regarding the position statement on medical cannabis by the American Academy of Sleep
Medicine (AASM), 1 the opportunity cost of banning cannabis program referrals and …

The legalization of cannabis for medicinal, and in some countries, recreational, purposes in
addition to growth in the cannabis industry has meant that cannabis use and interest in the …

As always, this issue of JSR encompasses a broad overview of the most recent
developments in sleep medicine and sleep research. For aspects of sleep medicine, this …

Sleep plays a crucial role in our overall well-being, impacting our physical health, mental
clarity and emotional balance. Unfortunately, 1 in 4 adults in Canada experience sleep …

The recent trend for legalization of medicinal cannabis and cannabinoid-containing
products, together with their soporific effects, has led to a surge of interest of their potential …